The formation of a tumor immune barrier, containing CAF and secreted phosphoprotein 1 (SPP1)+ macrophages, at the tumor border of HCC patients correlates with reduced response to anti-PD-1 therapy271and, therefore, stroma-modifying therapy is an interesting approach for combination therapy. The gene discussed is SPP1; the disease is hepatocellular carcinoma.